penetration and efficacy. Further, body weight-based vancomycin dosages of less than 30 mg/kg/day seldom cause severe nephrotoxicity. 9 However, previous evidence has indicated that a serum trough concentration >15 mg/l might be associated with increased nephrotoxicity. 15, 16 A vancomycin dosing nomogram to achieve high trough concentrations has been assessed in Taiwanese patients. 17 In China, the patients receiving vancomycin are usually critically ill and their drug clearance rate may be altered drastically, making them more susceptible to nephrotoxicity. However, data regarding the associations between serum trough concentrations, efficacy, and toxicity in the northwest of China are lacking. Therefore, the goal of the present study was to evaluate the risk factors of nephrotoxicity in these critically ill patients receiving vancomycin therapy, including the drug dosing regimen, serum trough concentration, age, body weight, and incidence of nephrotoxicity. The results of this study will provide new useful evidence to guide vancomycin treatment in China.
Patients and methods

Patients
A retrospective cohort study was conducted in Xijing Hospital of the Fourth Military Medical University between March 2014 and January 2015. Adult patients who received vancomycin for at least 48 h were identified. Patients with renal dysfunction (receipt of dialysis or creatinine clearance <30 ml/min), those treated with vancomycin during the same hospital stay, those receiving concomitant nephrotoxins (aminoglycosides, amphotericin B, radiocontrast dye, and vasopressors), and those without available laboratory data were excluded from the evaluation.
For all patients included in this study, the following data were collected: age, gender, actual body weight, diagnosis, type of infection, intensive care unit (ICU) admission, concurrent medication, vancomycin dosing, vancomycin trough concentration, and laboratory measurements. Their medical records and related documents were obtained with informed consent from the central database of Xijing Hospital.
Design and data collection
Clinicians prescribed vancomycin in accordance with the guidelines and recommendations of the Infectious Diseases Society of America when severe MRSA infections were confirmed. Actual body weight-based dosing ranged from 20 to 45 mg/kg/day. The most frequently used dosing in the study hospital was 1.5-2 g every day. Vancomycin was administered by intermittent intravenous infusion.
Blood samples for the measurement of the vancomycin trough concentration were obtained within 30 min before the administration of the fifth dose of vancomycin. This trough level represents the stable serum trough concentration of the following period. Renal function was monitored constantly, before and during vancomycin therapy.
No severe side effects that required the discontinuation of vancomycin therapy occurred in this study. When the vancomycin trough concentration was higher than 25 mg/l, the vancomycin dosage was adjusted according to the patient's condition. If no methicillin-resistant strain was detected, the chemotherapy was de-escalated to a beta-lactam antibiotic.
Definitions
Renal function was assessed by measuring the urinary production and the serum concentration of creatinine, urea nitrogen, and cystatin. Nephrotoxicity was defined as an increase in serum creatinine (SCr) >0.5 mg/dl (44.2 mmol/l), or an increase in SCr >50% from the baseline level for at least 2 days. 18 
Statistical analysis
Univariate analysis was used to compare patients who developed nephrotoxicity with those who did not develop nephrotoxicity in regard to the age, body weight, and other basic characteristics. Data were analyzed with the Chi-square test. Multivariate analysis was used to identify independent risk factors of vancomycin-associated nephrotoxicity. IBM SPSS Statistics version 20.0 (IBM Corp., Armonk, NY, USA) was used for the analysis of significant differences.
Data were presented as the mean and standard deviation (SD). A p-value of 0.05 or less indicated a statistically significant difference.
Results
Patient characteristics
Among 172 courses of vancomycin identified, 90 patients met the inclusion criteria. The cohort consisted of 59 men and 31 women. Their mean (SD) age was 46.3 (15.6) years and their mean (SD) body weight was 62.4 (9.4) kg. The sources of MRSA infection were bloodstream (52.2%), pulmonary (18.9%), CNS (14.4%), skin/soft tissue (4.4%), genitourinary (4.4%), gastrointestinal (2.2%), osteomyelitis (2.2%), and endocarditis (1.1%).
Administration of vancomycin
The median length of vancomycin therapy was 9 days. The mean (SD) dosage was 31.3 (5.4) mg/kg/day. Thirty-four patients were given vancomycin dosages between 20 and 30 mg/kg/day (25.5 AE 2.8), and 46 patients were given doses between 30 and 38 mg/kg/day (33.2 AE 2.3). Ten patients were given >38 mg/kg/day (40.4 AE 1.6). The mean (SD) vancomycin serum concentration was 10.1 (5.4) mg/l. Fifty-eight patients had a mean concentration between 5 and 10 mg/l (6.9 AE 1.7), and 25 patients had a mean concentration between 10 and 20 mg/l (13.5 AE 3.0). Seven patients had a concentration higher than 20 mg/l (23.9 AE 2.1). There were two deaths due to multiple organ failure. All other patients achieved clinical cure by the time of discharge from the hospital.
Incidence of nephrotoxicity
Among 90 patients, there were two mortalities due to multiple organ failure. A total of 14 (15.6%) patients developed nephrotoxicity while receiving vancomycin therapy. None of these patients showed severe symptoms or needed dialysis. Their renal dysfunction was transient and laboratory measurements returned to normal levels before hospital discharge.
The mean (SD) SCr of all patients prior to vancomycin treatment The actual body weight and dosing showed significant differences between patients with and without nephrotoxicity. However, in terms of the age, gender, length of vancomycin treatment, vancomycin serum trough concentrations, and baseline SCr levels, there were no significant differences. The results are presented in Table 1 .
Multivariable data analysis showed that a vancomycin dosage >38 mg/kg/day and a vancomycin serum trough level >20 mg/l were both independent predictors of renal toxicity. The results are shown in Table 2 .
Discussion
In this retrospective study, 15.6% of 90 critically ill patients developed nephrotoxicity during vancomycin treatment. It was demonstrated that patients receiving weight-based dosages higher than 38 mg/kg/day and with a serum trough concentration greater than 20 mg/ml were more likely to develop nephrotoxicity. It was also noticed that the incidence of nephrotoxicity was higher than in previous studies that have reported standard vancomycin dosing (30 mg/kg/day), in which this caused around 5% of patients to develop nephrotoxicity. 4, 5 This might be due to the fact that 11.1% of patients were receiving dosages around 40 mg/kg/day and all patients were in a critical state.
The relationships between vancomycin dosing, serum trough concentrations, and efficacy or nephrotoxicity have been documented by other authors. 4, [19] [20] [21] Vancomycin prescribed at a high dose and an extended duration of use appear to be the risk factors for developing nephrotoxicity. 22, 23 Larger doses and increased vancomycin trough concentrations have been shown to be involved in the occurrence of renal injury. 8, 24, 25 For instance, vancomycin-induced nephrotoxicity occurred when the dosing regimen maintained the trough concentration between 15 and 20 mg/l. 15, 16 Han et al. also reported that a trough concentration over 12.1 mg/l was a major risk factor for nephrotoxicity in patients undergoing therapeutic vancomycin monitoring. 26 The nephrotoxicity might also be a particular matter in high-dose vancomycin therapy for MRSA infections. [27] [28] [29] Obviously, regular monitoring of vancomycin dosing is critical for the prevention of nephrotoxicity. 30, 31 The increased dosing of vancomycin treatment was supposed to counter the gradual creeping of the vancomycin MIC in MRSA isolates. 1, 14 Although weight-based vancomycin dosing has been recommended in the guidelines, 6, 7, 9 the association between different dosing and nephrotoxicity is yet to be clarified, especially in the northwest area of China. From the authors' observations, aggressive dosages are more likely to cause nephrotoxicity. Evidence suggests that a solution to this problem might be the use of continuous infusion, which could replace the fluctuating concentrations with a plateau concentration of 20-25 mg/l. This could also maximize treatment efficacy and reduce nephrotoxicity. Studies performed by DiMondi and Rafferty 32 and Hutschala et al. 33 have shown that continuous infusion results in a lower rate of nephrotoxicity developing compared with intermittent infusion. 32, 33 Moreover, previous evidence has shown that the incidence of vancomycin-induced nephrotoxicity may also be related to patient age, [34] [35] [36] [37] the severity of illness, 38, 39 chronic kidney disease, and methicillin-resistant pneumonia. 40, 41 In the present study, the incidence of nephrotoxicity of 15.6% also implies that a critically ill state might be a risk factor for renal toxicity with vancomycin therapy. Among the 14 patients who developed nephrotoxicity, 10 were male and four were female, suggesting that there may also be a gender difference in relation to the incidence of nephrotoxicity.
The possible mechanisms of vancomycin-induced nephrotoxicity have also been investigated previously. 42 For instance, oxidative stress from mitochondrial superoxide production might contribute to vancomycin-related renal injury, 43, 44 while the manipulation targeting superoxide dismutase to renal tubule cells has been shown to improve the vancomycin-induced nephrotoxicity in rodents. 45 The serum neutrophil gelatinaseassociated lipocalin could also influence renal function in patients on vancomycin treatment, 46 and the functional state of the kidney in children might lead to susceptibility to vancomycin toxicity. 47 This study has several limitations. First, this was a retrospective investigation of MRSA patients in only one institution. An observation bias of the data cannot be excluded. Second, the patients receiving vancomycin in the northwest of China were mostly critically ill patients. Their vancomycin distribution and clearance status could be significantly altered, making them more susceptible to nephrotoxicity. Last, loading doses and pharmacokinetic monitoring of vancomycin have not yet been adopted in the study institution. Multicenter controlled studies with a larger sample are still needed to clarify the associations between dosing, serum trough concentrations, and nephrotoxicity. This would benefit these critically ill patients by ensuring efficacy and safety during vancomycin therapy.
In conclusion, the present results suggest that vancomycin dosing higher than 38 mg/kg/day and trough concentrations greater than 20 mg/ml might be associated with an increased risk of developing nephrotoxicity. These data may provide useful evidence to instruct clinicians for evaluating the vancomycin regimen in China. Ethical approval: The study was approved by the Research Ethics Committee of Xijing Hospital, the Fourth Military Medical University, China.
Conflict of interest: None.
